Defining "culprit mechanisms" in arrhythmogenic cardiac remodeling.
Nattel
Stanley
S
D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000502:physiology; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000473:pathology / Q000503:physiopathology*; D001281:Atrial Fibrillation / Q000473:pathology / Q000503:physiopathology; D004285:Dogs; D005355:Fibrosis; D006325:Heart Atria / Q000503:physiopathology; D006333:Heart Failure / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D023421:Models, Animal; D009206:Myocardium / Q000473:pathology; D016212:Transforming Growth Factor beta / Q000235:genetics / Q000502:physiology; D053773:Transforming Growth Factor beta1; D020257:Ventricular Remodeling / Q000187:drug effects / Q000502:physiology*
C508960:TGFB1 protein, human; C508961:Tgfb1 protein, mouse; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D000804:Angiotensin II